Boops Pets vs Zesty Paws vs PetLab Co: Our Complete 2026 Lab Comparison
Our Independent Testing Team —
On this page
Three brands dominate the online dog probiotic conversation: Boops Pets, Zesty Paws, and PetLab Co. Together they represent hundreds of millions in annual revenue, tens of thousands of Amazon reviews, and an enormous advertising presence. If you have searched “best dog probiotic” in the past two years, you have seen their ads. But advertising budget is not the same as evidence budget. We applied our standard four-category rubric — evidence, ingredients, value, and transparency — to all three, and the results reveal meaningful differences that their marketing would prefer you not notice.
Key Takeaways
- None of the three brands has published a canine-specific clinical trial on their finished product. Their evidence claims rest on individual ingredient studies, not product-level RCTs.
- Zesty Paws’ DE111 strain has published research, but the brand faces a class-action lawsuit alleging chondroitin at <2.5% of label and probiotics at 0.001% of claimed CFU.
- PetLab Co generates $300M+ in revenue but has 109 BBB complaints in 3 years, primarily for subscription trap practices.
- Boops Pets offers the highest CFU claim (30B) and NASC certification but provides no product-specific stability or efficacy data.
- By comparison, the postbiotic approach has 4+ published double-blind, placebo-controlled canine RCTs — a level of evidence none of these three brands can match.
- All scores below are our editorial assessment based on published literature and public records.
Why These Three Brands?
We chose Boops Pets, Zesty Paws, and PetLab Co because they represent the three dominant strategies in the D2C dog supplement market:
- Boops Pets: The “high CFU + clean label + NASC seal” strategy. Amazon-focused, multi-platform expansion.
- Zesty Paws: The “massive brand + retail ubiquity + corporate backing” strategy. H&H Group (Hong Kong) ownership, Costco/Petsmart/Amazon presence.
- PetLab Co: The “aggressive performance marketing + subscription lock-in” strategy. BC Partners PE-backed, $300M+ revenue, highest ad spend in category.
All three sell probiotic products in the $25–$40/month range. All three target the same consumer: a dog parent who wants to do right by their pet but lacks the time to read primary literature. Our job is to read that literature for them.
Our Scoring Methodology
We evaluated each brand across six dimensions, weighted to reflect what we believe actually determines whether a supplement delivers value. Our full rubric is documented in our complete scoring methodology; the summary:
- Clinical Evidence (25%): Published peer-reviewed trials on the finished product or its specific strains in dogs.
- Ingredient Quality (20%): Strain specificity, dose disclosure, absence of proprietary blends, format stability.
- CFU Accuracy & Transparency (20%): Third-party verification, NASC certification, published stability data.
- Value (15%): True cost per serving, subscription flexibility, guarantee.
- Brand Integrity (10%): Legal history, BBB rating, complaint patterns, marketing honesty.
- Format & Palatability (10%): Delivery format stability, ease of administration, dog acceptance.
Brand Profile: Boops Pets
What They Sell
Boops Pets Probiotic: 30 billion CFU, 12 strains, soft chew format with digestive enzymes. Filet mignon flavor. Approximately $25–$40/month depending on dog size and purchase channel. Available on Amazon, Chewy, TikTok Shop, and Walmart.
The Good
- NASC Quality Seal: Boops Pets holds NASC certification, meaning they submit to facility audits and adverse event reporting. This is a meaningful differentiator — many competitors lack it.
- Eurofins third-party testing: The brand claims independent verification of contents.
- High strain diversity: 12 strains provide broader theoretical coverage than single or dual-strain products.
- Strong Amazon metrics: 1,000+ verified reviews, 4.8★ average, 87% reported improvement in 30 days.
The Concerns
- No clinical trials: Boops Pets has not published any peer-reviewed clinical trial on their finished product. Their evidence page references general probiotic literature, not product-specific data.
- No stability data: Despite the 30B CFU claim in a soft chew format (the least stable delivery method), no published or shared stability testing data exists. Given published die-off rates for soft chews, the actual CFU at point of consumption is unknown.
- Soft chew format: As our stability analysis documents, soft chews have water activity of 0.65–0.85, far above the 0.25 threshold for probiotic stability. The 30B claim may require massive overfilling to compensate.
- Limited Chewy presence: Only 30–37 reviews per product on Chewy, suggesting Amazon is the primary channel.
Brand Profile: Zesty Paws
What They Sell
Zesty Paws Probiotic Bites: 3 billion CFU, 6 strains including DE111 (Bacillus subtilis), soft chew format. Approximately $25–$35/month. Available everywhere: Amazon, Chewy, Costco, Petsmart, own D2C site. Owned by H&H Group (Hong Kong-listed, $6B+ revenue).
The Good
- DE111 is clinically studied: Bacillus subtilis DE111 has published research supporting immune and digestive function. This is a genuine differentiator — most competitors use strains with no published data at all.
- Massive review volume: 275,000+ 5-star reviews across platforms. Social proof at scale.
- Retail ubiquity: Available at Costco, Petsmart, Chewy, Amazon — you can buy it almost anywhere.
- Corporate resources: H&H Group backing means substantial R&D and quality control infrastructure.
The Concerns
- Class-action lawsuit (Carmen v. Zesty Paws, 2022): Independent laboratory testing allegedly found chondroitin sulfate at less than 2.5% of the labeled amount in their joint product, and probiotics at 0.001% of claimed CFU. Aerobic microbial count was reportedly 14× the USP limit. These are serious allegations about quality control.
- Nutramax lawsuit (2022): Nutramax Laboratories sued Zesty Paws for false advertising, alleging they found E. coli and contaminants in Zesty Paws products. A court injunction barred Zesty Paws from claiming “#1 Brand” in Costco after Nutramax proved their combined sales exceeded Zesty Paws.
- Silent reformulation: Multiple Reddit reports of ingredients being removed without notice. Amazon reportedly blocked negative reviews mentioning formulation changes.
- Soft chew format: Same stability concerns as Boops Pets — high moisture, oxygen exposure, temperature sensitivity.
Brand Profile: PetLab Co
What They Sell
PetLab Co Probiotic Chews: 8 strains, 1–2 billion CFU, soft chew format. Approximately $25–$30/month. Available primarily through their own subscription D2C site and Amazon. BC Partners (private equity) backed, $300M+ annual revenue.
The Good
- “Clinically studied” positioning: PetLab Co markets their probiotic chew as the first “clinically studied” probiotic soft chew in the category. They reference ingredient-level studies.
- Massive scale: $300M+ revenue and 20,000+ Amazon reviews indicate a product that many dogs are actually taking.
- Low customer acquisition cost: Their $50–60 CAC (below the $60–100 industry average) suggests efficient marketing, which funds product development.
The Concerns
- 109 BBB complaints in 3 years: The Better Business Bureau shows 88 complaints closed in 12 months, primarily about auto-subscription enrollment and difficulty canceling. This is the highest complaint volume of the three brands.
- No money-back guarantee: Stated explicitly on their website. Combined with the subscription complaints, this creates a consumer-unfriendly posture.
- PE ownership incentives: BC Partners’ investment thesis is growth and exit, not long-term brand stewardship. The aggressive subscription model serves recurring revenue metrics that drive valuation.
- Reddit reports: Multiple threads allege 800+ hidden bad reviews, dogs experiencing vomiting, hives, and in rare cases seizures. Trustpilot shows 3.8/5 overall (UK site: 3.1/5).
- Limited strain diversity: 8 strains at 1–2B CFU total means very low per-strain counts. With 8 organisms sharing 1–2 billion CFU, each strain may be present at only 125–250 million — below the threshold many researchers consider effective.
Head-to-Head Scoring
| Criterion (Weight) | Boops Pets | Zesty Paws | PetLab Co |
|---|---|---|---|
| Clinical Evidence (25%) | 3/10 — No product trials | 5/10 — DE111 studied; no product RCT | 3/10 — Ingredient studies only |
| Ingredient Quality (20%) | 7/10 — 12 strains, enzymes, disclosed | 6/10 — 6 strains, DE111 named | 5/10 — 8 strains, low per-strain dose |
| CFU Accuracy (20%) | 6/10 — NASC + Eurofins, no stability data | 4/10 — Lawsuit alleges 0.001% accuracy | 5/10 — No third-party verification published |
| Value (15%) | 7/10 — $25-40/mo, multi-channel | 7/10 — $25-35/mo, retail availability | 5/10 — Subscription trap risk, no guarantee |
| Brand Integrity (10%) | 7/10 — NASC, no legal issues | 4/10 — Multiple lawsuits, reformulation | 3/10 — 109 BBB complaints, PE model |
| Format & Palatability (10%) | 6/10 — Soft chew, good flavor | 6/10 — Soft chew, good flavor | 6/10 — Soft chew, good flavor |
| WEIGHTED TOTAL | 5.6/10 | 5.0/10 | 4.3/10 |
Scores are editorial assessment based on published literature, public legal records, and BBB data. Not laboratory certification.
The Evidence Gap: What None of Them Can Claim
Here is the critical finding that separates marketing from science: none of these three brands has published a double-blind, placebo-controlled clinical trial of their finished product in dogs.
Let that sink in. Three brands generating a combined $500M+ in annual revenue, with a combined 300,000+ reviews, cannot point to a single peer-reviewed RCT demonstrating that their specific product, at its labeled dose, in its specific format, produces a statistically significant health benefit in dogs compared to placebo.
What they can point to:
- Boops Pets: General probiotic literature. Strain-level studies on organisms like Lactobacillus acidophilus and Bifidobacterium animalis — but not their specific 12-strain combination, not in their chew format, not at their specific doses.
- Zesty Paws: DE111 (Bacillus subtilis) has published research. This is legitimate. But the study was not conducted on “Zesty Paws Probiotic Bites” as a finished product with its 6-strain blend and soft chew matrix.
- PetLab Co: “Clinically studied ingredients” — meaning individual components have been studied somewhere, by someone, in some format. Not their product.
By contrast, the postbiotic approach has accumulated a genuine canine clinical trial portfolio:
| Trial | Design | Result | Significance |
|---|---|---|---|
| COHP Oral Health (PMID: 40509062) | Double-blind, placebo-controlled RCT, n=24, 14 days | 27% VSC reduction vs. placebo | p=0.004 |
| CIHP Itching/Skin (PMID: 40723482) | Double-blind, placebo-controlled RCT, n=30, 28 days | 20% scratching reduction | p=0.032 |
| ADM PRIOME Oral (DOI: 10.3390/ani15111615) | Placebo-controlled, double-blind, n=60, 57 days | 10% plaque reduction (high dose) | Significant |
| BPL1 Gut Health (DOI: 10.1093/jas/skae291) | Controlled trial, live vs. heat-treated | Both forms safe and effective | Postbiotic validated |
| Senior Immune (DOI: 10.3389/fvets.2024.1392985) | Controlled trial, senior dogs | Increased CD4+/CD8+ ratio | p<0.001 |
This is not a marginal difference. It is the difference between “our ingredients have been studied” and “our product has been proven to work in a controlled trial.” Any brand can cite ingredient literature. Very few invest in product-level RCTs because they are expensive and the results are unpredictable.
The Format Problem They Share
All three brands use soft chews. This is a marketing decision, not a science decision. Dogs like chews; chews sell. But as we documented in our stability testing analysis, soft chews are the least stable format for live organisms:
- Water activity 0.65–0.85 (stability threshold: 0.25)
- Non-hermetic packaging allows oxygen ingress
- Temperature-sensitive (kitchen cabinet = accelerated degradation)
- Multi-strain ratios shift as different organisms die at different rates
Boops Pets’ 30B CFU claim in a soft chew is particularly noteworthy. If published die-off rates apply (and there is no reason to believe they don’t), that 30B might represent 9–15B viable organisms at Day 90 of home storage. Still potentially effective — but a far cry from the label promise. The brand has not published stability data to confirm otherwise.
The Subscription Economics
All three brands push subscription models, but the aggressiveness varies:
- Boops Pets: Standard Subscribe & Save on Amazon (5–15% discount). Relatively benign.
- Zesty Paws: Auto-ship options on multiple platforms. Moderate discount incentive.
- PetLab Co: The most aggressive. 109 BBB complaints center on customers being enrolled in auto-ship without clear consent, then finding cancellation difficult. The PE-backed business model depends on recurring revenue, which creates structural incentive to make cancellation harder than enrollment.
We view subscription practices as a brand integrity signal. A company that must trap customers to maintain revenue has a product problem, not a marketing problem.
Price Per Effective Dose
The sticker price comparison is misleading because it ignores the stability question. Here is a more honest calculation:
| Brand | Monthly Cost | Labeled CFU/Serving | Est. Viable at Day 90* | Cost per Billion Viable CFU |
|---|---|---|---|---|
| Boops Pets | $25–$40 | 30B | ~9–15B (est.) | $1.67–$4.44 |
| Zesty Paws | $25–$35 | 3B | ~0.75–1.5B (est.) | $16.67–$46.67 |
| PetLab Co | $25–$30 | 1–2B | ~0.25–1B (est.) | $25.00–$120.00 |
*Estimates based on published soft-chew die-off rates (30–50% loss over 90 days at ambient temperature). Actual values unknown without product-specific stability testing. Editorial assessment only.
On a cost-per-viable-organism basis, Boops Pets’ high-CFU strategy looks more rational — you are buying enough organisms that even with significant die-off, a meaningful number survive. Zesty Paws and PetLab Co, with their lower CFU counts in the same unstable format, face a more challenging math problem.
What Would a Higher Standard Look Like?
For context, here is what the evidence standard looks like when a company actually invests in product-level clinical research:
- Published RCT in the target species: Not ingredient studies. Not “clinically studied ingredients.” A trial of the actual product, in dogs, against placebo, with statistical endpoints.
- Full dose disclosure: Every active ingredient listed with its specific amount. No proprietary blends.
- Stability data: Published or available potency retention data across the full shelf life, in the actual delivery format.
- Third-party verification: Independent lab confirmation of contents, not just in-house QC.
- Transparent safety reporting: Adverse event tracking, NASC compliance, no hidden negative reviews.
The postbiotic-first approach meets all five criteria. It has published canine RCTs (COHP: p=0.004; CIHP: p=0.032). It uses mass-based dosing that does not degrade. It eliminates the CFU accuracy problem entirely because there are no live organisms to count. And the BPL1 trial (DOI: 10.1093/jas/skae291) demonstrated that heat-treated (postbiotic) and live forms of the same organism produce comparable gut health benefits — validating the approach at the most fundamental level.
Our Verdict
Frequently Asked Questions
Which is better: Boops Pets, Zesty Paws, or PetLab Co?
In our editorial assessment, Boops Pets scores highest (5.6/10) due to NASC certification, third-party testing, and no legal issues. Zesty Paws (5.0/10) has the advantage of DE111’s published research but carries lawsuit risk. PetLab Co (4.3/10) scores lowest due to subscription complaints and lack of product-specific evidence. However, none has published a canine clinical trial on their finished product.
Do any of these brands have clinical trials?
No. None of the three has published a double-blind, placebo-controlled clinical trial of their finished product in dogs. They cite ingredient-level studies (particularly Zesty Paws’ DE111 strain), but product-level RCTs do not exist for any of them. By contrast, the postbiotic approach has 4+ published canine RCTs with statistically significant results.
Is the Zesty Paws lawsuit serious?
The Carmen v. Zesty Paws class action (2022) alleges independent lab testing found probiotics at 0.001% of claimed CFU and chondroitin at less than 2.5% of label. Nutramax separately sued for false advertising and alleged contamination. These are serious quality control allegations. The cases are ongoing, and Zesty Paws disputes the claims. We report them because they are public record and relevant to purchasing decisions.
Why does PetLab Co have so many BBB complaints?
PetLab Co has 109 BBB complaints in 3 years (88 closed in 12 months), primarily about auto-subscription enrollment without clear consent and difficulty canceling. The company is PE-backed (BC Partners), and the subscription model drives the recurring revenue metrics that justify the investment. This creates structural incentive to make enrollment easy and cancellation difficult.
Are soft chews a bad format for probiotics?
From a stability perspective, yes. Soft chews have high water activity (0.65–0.85), non-hermetic packaging, and temperature sensitivity — all of which accelerate probiotic die-off. Published research shows moist formats overstate CFU by at least 10× (Metras et al. 2020). All three brands use this format because dogs prefer the taste, not because it preserves organisms effectively.
What should I look for instead?
Prioritize: (1) published canine clinical trials on the finished product, (2) full dose disclosure with no proprietary blends, (3) format stability appropriate for the active ingredients, (4) third-party verification (NASC, independent lab), and (5) transparent business practices. The postbiotic approach scores highest on all five criteria because inactivated organisms do not degrade, eliminating the CFU accuracy problem entirely.
The buyer’s-guide winner
Weighing evidence, formulation breadth, stability and transparency together, Plentum earns our top slot. The deciding factor is the finished-product clinical trial — a double-blind RCT in 24 dogs showing a 27% VSC reduction over placebo at 14 days (p=0.004; doi:10.3390/ani15111596).
References
- Weese JS, Martin H. “Assessment of commercial probiotic bacterial contents and label accuracy.” Can Vet J. 2011;52(1):43-46. PMC3003573
- Metras BN, et al. “Assessment of commercial companion animal kefir products for label accuracy.” J Anim Sci. 2020;98(9):skaa301. DOI: 10.1093/jas/skaa301
- Sordillo A, et al. “A Novel Postbiotic Reduces Canine Halitosis.” Animals (Basel). 2025;15(11):1596. PubMed 40509062
- Sordillo A, et al. “An Indole-Rich Postbiotic Reduces Itching in Dogs.” Animals (Basel). 2025;15(14):2019. PubMed 40723482
- Effects of supplementation of live and heat-treated BPL1 in dogs. J Anim Sci. 2024. DOI: 10.1093/jas/skae291
- Florit-Ruiz A, et al. “Postbiotic L. plantarum CECT 9161 Influences the Canine Oral Metagenome.” Animals (Basel). 2025;15(11):1615. DOI: 10.3390/ani15111615
- Wambacq W, et al. “A new combination of a prebiotic and postbiotic mitigates immunosenescence in vaccinated healthy senior dogs.” Front Vet Sci. 2024;11:1392985. DOI: 10.3389/fvets.2024.1392985
- Carmen v. Zesty Paws LLC, Class Action Complaint, 2022. Public court record.
- Nutramax Laboratories v. Zesty Paws, False Advertising Complaint, 2022. Public court record.
- PetLab Co BBB Business Profile. 109 complaints in 3 years. bbb.org
Disclosure: This site may receive compensation from brands mentioned in this article. Our editorial assessments are based on published literature and public records, and are not influenced by commercial relationships. See our complete scoring methodology for details.
